Alnylam Pharmaceuticals Inc’s recent filing unveils that its Officer Fitzgerald Kevin Joseph acquired Company’s shares for reported $0.85 million on Jan 13 ’26. In the deal valued at $369.10 per share,2,290 shares were bought.
Then, Fitzgerald Kevin Joseph sold 12,128 shares, generating $5,483,990 in total proceeds. Upon selling the shares at $452.18, the CSO & EVP, Head of Research now owns 21,264 shares.
Before that, Fitzgerald Kevin Joseph bought 12,128 shares. Alnylam Pharmaceuticals Inc shares valued at $5,445,472 were divested by the Officer at a price of $449.00 per share.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who increased its forecast for the stock in early August from “an Underperform” to “a Peer perform”. Oppenheimer also remained covering ALNY and has increased its forecast on August 04, 2025 with a “an Outperform” recommendation from previously “Perform” rating.
Price Performance Review of ALNY
On Tuesday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock fall -0.26% to $369.96. Over the last five days, the stock has lost -8.97%. Alnylam Pharmaceuticals Inc shares have risen nearly 55.46% since the year began. Nevertheless, the stocks have fallen -6.96% over the past one year.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2025-12-31, growing by 1.57 million shares to a total of 5.53 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 3.96 million shares. There was a rise of 28.42%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 21, 2025 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $385 price target.
